Salute e Benessere

Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director

Lisa brings over twenty years of experience leading laboratory project teams through research, development, validation (clinical and analytical) and implementation of diagnostic tests. She has extensive experience overseeing clinical and bioanalytical laboratories and associated quality systems, managing clinical assay development, validation projects, quality improvement and laboratory personnel. Lisa brings over twenty years of experience leading laboratory project teams through research,...
PR Newswire
29/04/2024

Immunovia streamlines lab operations with move to Research Triangle Park, North…

Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs. The new space in Research Triangle Park (RTP) will be significantly smaller and less expensive than the company's existing lab in Marlborough, Massachusetts. The lower cost of labor in Research Triangle Park should enable the company to staff the new lab at a lower cost. Moving its lab and U.S. headquarters toResearch Triangle Park...
PR Newswire
29/04/2024

Sectra and Leica Biosystems first in the world to gain FDA clearance to utilize…

"Given the rigorous review and clearance process leading up to this point, I see the new FDA clearance as strong proof of the quality of our solution. It is also an enabler for pathology departments to benefit from the latest scanner technology as well as the standardization that is happening within digital pathology. We have already seen how our customers utilize digital pathology to improve patient care, especially in complex cases such as cancer, and I am proud to be part of that…
PR Newswire
29/04/2024

Compass Pathways and Journey Clinical establish research collaboration agreement…

The first phase of the collaboration comprises an in-depth information exchange on the COMP360 psilocybin treatment delivery model. Together, Compass and Journey Clinical will work to better understand the patient care experience, depression patient pathways and care reimbursement processes, and explore innovative care pathways for TRD patients, should COMP360 psilocybin treatment be approved. They will conduct research into therapist training, support, and education, and exchange...
Nasdaq GlobeNewswire
29/04/2024

Immunovia publishes the annual report for 2023

For more information, please contact:Karin Almqvist LiwendahlChief Financial Officerkarin.almqvist.liwendahl@immunovia.com+46 709 11 56 08 For more information, please contact:Karin Almqvist Liwendahl Chief Financial Officerkarin.almqvist.liwendahl@immunovia.com+46 709 11 56 08 Immunovia in brief Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and...
PR Newswire
29/04/2024

Transactions in Connection with Share Buy-back Program Genmab

Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from April 22, 2024 to April 26, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
29/04/2024

Huma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder…

Enabling Better Care Experiences for Cancer Patients Enabling Better Care Experiences for Cancer Patients The bladder cancer treatment companion app developed by Huma and Merck KGaA, Darmstadt,Germany, is designed to support patients and caregivers in navigating the complexities of bladder cancer treatment by providing a reliable source of information and support throughout the treatment journey. Built in collaboration with healthcare professionals and leading patient organisations, the...
PR Newswire
29/04/2024

Hurom Takes Global Action to Protect Juicer Patents

Despite maintaining a lenient policy on patented technologies to foster ecosystem development, the rise of unauthorized imitations, especially in the Chinese market, has prompted Hurom to take action. Despite maintaining a lenient policy on patented technologies to foster ecosystem development, the rise of unauthorized imitations, especially in the Chinese market, has prompted Hurom to take action. However, unauthorized copying of patented technologies has continued inthe United States...
PR Newswire
29/04/2024

Biosimilar Testing and Development Services Market to Hold $7.8 Billion, by 2032…

Request Sample of the Report on Biosimilar Testing and Development Services Market Forecast - https://www.alliedmarketresearch.com/request-sample/3972 Request Sample of the Report on Biosimilar Testing and Development Services Market Forecast -https://www.alliedmarketresearch.com/request-sample/3972 Factors influencing growth of the market The global biosimilar testing and development services industry is driven by a surge in R&D investments on biosimilar testing, patent...
PR Newswire
29/04/2024

Lenire from Neuromod delivers tinnitus improvement 'not demonstrated for any…

Lenire® is a bimodal neuromodulation device which has been proven to provide long term relief from tinnitus that lasts for at least 12-months after treatment in large scale clinical trials. [1],[3]Lenire's bimodal neuromodulation works by delivering mild pulses to the tongue, through an intra-oral component called the Tonguetip®. To treat tinnitus, it works in concert with auditory stimulation through headphones to promote long-term changes in the brain. In Lenire's most recent...
PR Newswire
29/04/2024

Smart Blood Analytics Swiss Achieves EU-MDR Certification for VIRUS vs. BACTERIA…

Antimicrobial resistance (AMR) poses a significant threat to global public health and development, contributing to millions of deaths annually. Mainly driven by the misuse and overuse of antibiotics, AMR undermines the effectiveness of treatments for infectious diseases, putting modern medical advancements at risk and increasing healthcare costs substantially. The World Health Organization (WHO) emphasizes preventing infections, ensuring universal access to quality diagnosis and treatment, and…
PR Newswire
29/04/2024

Immunovia Publishes Interim Report for January-March 2024

Significant events after the period Significant events after the period CEO's comments I am proud to report that we delivered on our promises in transforming Immunovia to a new and more agile company with a significantly lower cost base, faster pace, greater efficiency, and better results. Our new test demonstrated positive results in the model-development study, validating our decision from last summer to shift resources from IMMray™ PanCan-d to the new product. We are...
PR Newswire
29/04/2024

Philips delivers first-quarter results in line with 2024 performance improvement…

First-quarter highlightsGroup sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US (provision recognized of EUR 982 million)Income from operations EUR -824 million, including above provisionAdjusted EBITA margin of 9.4% of salesFree cash outflow of EUR 336 millionEUR 540 million agreement reached with insurers for Respironics recall-related...
Nasdaq GlobeNewswire
29/04/2024

Addex Provides Update on ADX71149 Phase 2 Epilepsy Study

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or...
Nasdaq GlobeNewswire
29/04/2024

INTREPID Alliance Landscape of Promising Antivirals in Clinical Development…

Globalization, urban expansion, and exploitation of natural habitats increase the chances of facing new and known pathogens with the potential to cause pandemics. One recent risk model indicates a 27.5 percent chance that a pandemic as deadly as COVID-19 could take place in the next ten years.2 Pandemic preparedness strategies, including medical countermeasures such as the use of antivirals, can help to mitigate the severity of a future outbreak. Globalization, urban expansion, and…
PR Newswire
29/04/2024

Financière de Tubize - Dividend approval

Dividend confirmation Regulated information - 26 april 2024The general shareholders meeting of 26 April 2024 has approved the annual accounts as at 31 December 2023, including the distribution of a gross dividend of € 0.97 per share.The dividend will be payable as from 3 May 2024 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 19.Ex-coupon 30 April 2024 Record date 2 May 2024 Payment date 3 May 2024
Nasdaq GlobeNewswire
27/04/2024

Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 -…

Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries. These tests serve vital functions in diagnosing conditions such as polycystic ovary syndrome (PCOS) and primary ovarian insufficiency, as well as in guiding treatment in various reproductive procedures, including in vitro fertilization (IVF). Challenges include high costs and a lack of widespread awareness, particularly in regions with limited resources…
PR Newswire
27/04/2024

Report from Orexo AB's annual general meeting, 26 April 2024

The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be five with no deputy board members. James Noble, Staffan Lindstrand, Fred Wilkinson, Christine Rankin and Robin Evers were re-elected as ordinary board members. James Noble was elected as chairman of the board. Ernst & Young Aktiebolag was re-elected as auditor. The annual general meeting in Orexo AB (publ) on26 April…
PR Newswire
26/04/2024

BioSenic publishes on its website the restructuring plan submitted to the…

PRESS RELEASE - PRIVILEGED INFORMATIONMont-Saint-Guibert, Belgium, 26 April 2024, 17:30 CET –BioSenic(Euronext Brussels and Paris: BIOS),the clinical-stage company specializing in serious autoimmune and inflammatory diseases, as part of the global restructuring plan announced on 11 April 2024, today announces the publication on its website of the following documentation :The restructuring plan covering the years 2024-2030 submitted to the Enterprise Court of Nivelles –...
Nasdaq GlobeNewswire
26/04/2024

United Imaging Healthcare Releases 2023 ESG Report, Advancing Mission of Equal…

Innovation remains a central focus for United Imaging Healthcare's development strategy. In 2023, the company has achieved 1,118 new patent applications and 886 newly granted patents, with a total of 4,134 granted patents. Additionally, United Imaging Healthcare is committed to excellence in product safety and quality by refining its quality control processes across the entire product lifecycle, including updating 45 quality management policies to align with international standards and…
PR Newswire
26/04/2024

Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron)…

The CHMP recommendation will now be reviewed by the European Commission (EC), which may decide on the marketing authorisation (MA) for OBGEMSA™ (vibegron). The decision will then be applicable to all member states of the European Union as well as toIceland,LiechtensteinandNorway. "We are very pleased to have received this positive opinion from the CHMP for OBGEMSA™ . If approved, this innovative therapeutic solution has the potential to help patients suffering from...
PR Newswire
26/04/2024

Oligonucleotide Synthesis Market Worth $19.7 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350 Browse in-depth TOC on "Oligonucleotide Synthesis Market" 546 - Tables 67 - Figures 454- Pages Oligonucleotide Synthesis Market Scope: Probes accounted for the second-largest segment of the synthesized oligos product segment in 2023. Probes are an important...
PR Newswire
26/04/2024

Bulletin from annual general meeting in Medicover AB (publ)

The AGM resolved, in accordance with the proposal from the nomination committee, that the number of board members appointed by the shareholders' meeting shall be nine. Fredrik Stenmo, Peder af Jochnick, Anne Berner, Arno Bohn, Sonali Chandmal, Michael Flemming, Margareta Nordenvall, Fredrik Rågmark and Azita Shariati were re-elected as board members. Fredrik Stenmo was re-elected as the chairman of the board. The AGM resolved that the number of auditors shall be one without deputies and to…
PR Newswire
26/04/2024

New President Appointed for Nitto Denko Avecia Inc.

Ms. Cooper has an extensive background in the pharmaceutical space, starting her career as a Manufacturing Formulation Chemist for small molecules. She joined Nitto Avecia 19 years ago and has served in roles of increased responsibility in marketing, business development and project management. Most recently she has served as the Vice President, Business Development and played a critical role on Nitto Avecia's leadership team during the company's most recent period of rapid growth. Ms...
PR Newswire
26/04/2024
Altri  Comunicati